Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations
Standard
Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. / Van den Broeck, Thomas; van den Bergh, Roderick C N; Briers, Erik; Cornford, Philip; Cumberbatch, Marcus; Tilki, Derya; De Santis, Maria; Fanti, Stefano; Fossati, Nicola; Gillessen, Silke; Grummet, Jeremy P; Henry, Ann M; Lardas, Michael; Liew, Matthew; Mason, Malcolm; Moris, Lisa; Schoots, Ivo G; van der Kwast, Theodorus; van der Poel, Henk; Wiegel, Thomas; Willemse, Peter-Paul M; Rouvière, Olivier; Lam, Thomas B; Mottet, Nicolas.
in: EUR UROL FOCUS, Jahrgang 6, Nr. 2, 15.03.2020, S. 231-234.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations
AU - Van den Broeck, Thomas
AU - van den Bergh, Roderick C N
AU - Briers, Erik
AU - Cornford, Philip
AU - Cumberbatch, Marcus
AU - Tilki, Derya
AU - De Santis, Maria
AU - Fanti, Stefano
AU - Fossati, Nicola
AU - Gillessen, Silke
AU - Grummet, Jeremy P
AU - Henry, Ann M
AU - Lardas, Michael
AU - Liew, Matthew
AU - Mason, Malcolm
AU - Moris, Lisa
AU - Schoots, Ivo G
AU - van der Kwast, Theodorus
AU - van der Poel, Henk
AU - Wiegel, Thomas
AU - Willemse, Peter-Paul M
AU - Rouvière, Olivier
AU - Lam, Thomas B
AU - Mottet, Nicolas
N1 - Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2020/3/15
Y1 - 2020/3/15
N2 - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.
AB - Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.
U2 - 10.1016/j.euf.2019.06.004
DO - 10.1016/j.euf.2019.06.004
M3 - SCORING: Journal article
C2 - 31248850
VL - 6
SP - 231
EP - 234
JO - EUR UROL FOCUS
JF - EUR UROL FOCUS
SN - 2405-4569
IS - 2
ER -